PCPCRC joins the Accelerating Clinical Trials (ACT) Canada Consortium

We are proud to announce that the PCPCRC is one of 28 networks working with the Accelerating Clinical Trials (ACT) Canada Consortium. The ACT Canada Consortium’s mission is to accelerate, optimize, and facilitate the conduct, implementation, and results translation from high-quality, high-impact randomized controlled trials to improve health in Canada and around the world. The PCPCRC was represented at the first annual ACT Canada Consortium Meeting held in Hamilton, Ontario on April 17th and 18th, 2023. The main objective of the meeting was to introduce all ACT committees and all 28 Networks under the ACT. These groups were connected with Canadian biotechnologies companies for potential future collaborations to improve health in Canada. The PCPCRC is represented in the ACT Scientific Committee, Patient Engagement Committee, and Equity, Diversity, and Inclusion Committee.


Going forward, ACT will hold funding opportunities to which our members can apply. Members applying to a call for funding proposals will be required to present their application to the PCPCRC membership, and an internal review of all applications will follow. The evaluation criteria will mimic those set out in the funding call from ACT to increase members’ likelihood of being granted funds. Please contact pcpcrc@bruyere.org for any questions.


Stay in the know with our latest news and resources

July 2, 2024
Two early-career investigators awarded seed funding in 2024 competition
July 1, 2024
PCPCRC member Dr. Vickie Baracos appointed Member of the Order of Canada
June 17, 2024
PCPCRC Semi-Annual Meeting takes place in Toronto
Patients and Caregivers